Sam Klempner, MD, Reviews ctDNA Role in Gastroesophageal Cancers


Sam Klempner, MD, spoke about utilizing ctDNA the treat nonmetastatic gastroesophageal cancers at 2022 IGCC.

At the 2022 International Gastric Cancer Conference, Sam Klempner, MD, of Massachusetts General Hospital, spoke to CancerNetwork® about the role of circulating tumor DNA (ctDNA) in patients with nonmetastatic gastroesophageal cancer and which patient populations are most likely to have have recurrence of their disease.


The main clinical question driving the interest in incorporating ctDNA into [the management of] nonmetastatic gastroesophageal cancers is that despite our best therapies—which are intensive and often toxic, including triplet chemotherapy and surgery in gastric cancer—we still have high recurrence rates. Identifying groups of patients who are either more or less likely to recur, and ultimately, by using some of these tests to incorporate into management, we may be able to define groups that we could intensify or potentially even de-intensify therapy for and achieve the same outcomes with a potentially less toxic regimen. The currently poor outcomes, the lack of current clinical predictors, and the potential toxicity of our treatments are the things that are driving better biomarkers.

Related Videos
Rates of obesity appear to correlate with increasing incidence of cancer in young populations, according to Monique Gary, DO, MSc, FACS.
Data from a ctDNA analysis of the phase 3 INTRIGUE study indicate that KIT mutational status may be associated with response to certain Tyrosine kinase inhibitors in GIST, according to an expert from the Yale Cancer Center in New Haven, Massachusetts.
Future research into the management of unresectable hepatocellular carcinoma may involve combining local therapies with checkpoint inhibitors like durvalumab and tremelimumab, according to Ghassan K. Abou-Alda, MD.
Patients with unresectable hepatocellular carcinoma who have recurrent disease following surgery or locally advanced diseases who will likely progress on local therapy may have an opportunity to benefit from tremelimumab and durvalumab following its FDA approval, according to Ghassan K. Abou-Alfa, MD.
Ghassan K. Abou-Alfa, MD, discusses the importance of improving access to novel therapies and combinations for patients with hepatocellular carcinoma across the world.
Ghassan K. Abou-Alfa, MD, spoke about the recent approval of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma, based on results from the phase 3 HIMALAYA trial.
Howard A. Burris, MD, highlighted previous findings of the phase 3 TOPAZ-1 trial assessing durvalumab plus gemcitabine and cisplatin vs placebo plus gemcitabine and cisplatin in advanced biliary tract cancer and patient-reported outcomes (PRO)data that were presented at 2022 ASCO.
Shubham Pant, MD discusses key findings from a basket trial examining the use of erdafitinib in patients with gastrointestinal cancers.
Related Content